PT-141

PT-141 is a synthetic peptide developed from melanotan II. Researchers studying melanotan II observed that test subjects reported changes in libido and arousal as a side effect. That signal was isolated and refined into PT-141, which was specifically designed to act on the central nervous system pathways involved in sexual arousal rather than the vascular pathways targeted by drugs like sildenafil. PT-141 was approved by the FDA in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder in premenopausal women.

Most well-known arousal medications work on the plumbing — they help blood reach where it needs to go. PT-141 works on the wiring upstream of the plumbing: the brain signals that say 'I want this.' That's why researchers and clinicians describe it as targeting desire rather than mechanics. Online, people describe it as the peptide for when the issue isn't physical capability but the missing 'switch.' It is studied in both men and women, and it is one of the only peptide-derived approaches to female sexual response with regulatory approval.

PT-141 is a melanocortin receptor agonist, primarily activating MC3R and MC4R in the central nervous system. These receptors influence hypothalamic circuits that regulate sexual arousal and motivation. By engaging this pathway, PT-141 acts upstream of vascular mechanisms, which is why it produces arousal effects independent of blood flow improvements. The same receptor activity also explains common observed effects such as facial flushing, nausea at higher doses, and transient skin darkening — all consistent with broader melanocortin pathway activation.

Isolated melanocortin peptide (no tanning effect). Targets sexual function via CNS.

1. PT-141
2. CNS receptor systems (melanocortin, BDNF, GABAergic or sleep-regulating)
3. Neurotransmitter and neurotrophic signalling
4. Cognition, mood, sleep and libido research endpoints

A plain-English read on how much published evidence currently exists for PT-141. These ratings describe the volume and maturity of the literature — not effectiveness, safety, or suitability for any use.

Current limitations: most compounds in this category are studied in preclinical or small-sample settings. Absence of large controlled human trials is the single biggest limitation to keep in mind when reading any summary of PT-141.

Lyophilized compounds are supplied as a dry powder. Concentration is simply the total amount in the vial divided by the volume of bacteriostatic water added:

Concentration (mg/mL) = total mg in vial ÷ mL of diluent added

Commonly supplied vial sizes

10mg vial

Worked concentration example

10mg + 2mL BAC water → 5mg/mL On U-100 insulin syringe:

• • 20 units = 1mg
• • 40 units = 2mg

Run your own numbers with the reconstitution calculator — it converts vial size and diluent volume into mg/mL and mcg/mL.

The figures below are reported here descriptively, because they are the values most frequently cited in publicly available research literature and reference material. They are not instructions, not a protocol, and not a recommendation. These compounds are supplied for laboratory research use only and are not approved by the FDA for human consumption.

Commonly cited amounts

1–2mg, 30–60 min before activity, subcutaneous

Commonly cited frequency

As needed (PRN)

Commonly cited study duration

PRN — not cycled

Peptides are supplied freeze-dried because peptide bonds degrade far faster in solution than in a dry state. Understanding storage is part of understanding why the powder form exists at all.

• •Lyophilized powder: stored refrigerated, typically stable for months to years.
• •Reconstituted solution: refrigerated at 2–8°C, generally discussed as stable for roughly 30–60 days.
• •Heat and direct light accelerate degradation — vials are kept cool and dark.
• •Reconstituted material is not re-frozen; ice crystal formation disrupts peptide structure.
• •Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which is what allows multi-day storage after reconstitution.

More detail in the storage & handling guide and how peptide quality is evaluated.

• •Hypoactive sexual desire disorder in premenopausal women
• •Erectile dysfunction not responsive to PDE5 inhibitors
• •Neurogenic and psychogenic arousal research
• •Melanocortin pathway pharmacology
• •Female sexual dysfunction studies
• •Hemorrhagic shock and blood pressure research (early development)

PT-141 is the dominant peptide discussed when arousal and libido come up in biohacking and longevity communities. The conversation is consistently split between people praising the central, desire-focused mechanism — and people warning about the side-effect profile: nausea, transient blood pressure changes, and pronounced facial flushing. Subcutaneous injection is the most discussed format; intranasal preparations are also mentioned. Forum chatter often emphasizes that PT-141 'works on a different switch' than Viagra-style drugs and that combining the two is unnecessary.

“The desire switch.”

PT-141 is most often discussed standalone — adding more is rarely the conversation. Where stacks are discussed, oxytocin is mentioned for emotional and bonding overlap, since PT-141 targets desire while oxytocin is associated with connection and post-arousal experience. Kisspeptin is sometimes mentioned in deeper hormonal-axis conversations. None of these combinations are recommendations.

PT-141 is a melanocortin receptor agonist developed from melanotan II that targets the central nervous system pathways of sexual desire and arousal. It is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder and is widely discussed in biohacking and research communities as the peptide that works on the upstream 'desire switch' rather than the vascular mechanics targeted by traditional ED drugs.